Hutchmed (HCM) said Sunday it initiated a late-stage clinical trial evaluating an experimental treatment combination for patients with relapsed or refractory diffuse large B-cell lymphoma in China.

The first participant received an initial dose of the targeted enzyme inhibitor alongside a standard chemotherapy regimen on March 20, the company said.

The randomized study intends to enroll roughly 240 individuals to compare the safety and efficacy of the drug combination against a placebo group, Hutchmed said.

The company also said the primary endpoint for the research includes measuring progression-free survival and overall survival rates among participants who are ineligible for transplantation.